arrow
A

Annamarja Lamminmäki

palliative medicine
H指数:9
被引数:577

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Disease-phase-specific resource utilization and healthcare costs in metastatic colorectal cancer: a subgroup analysis of the finnish RAXO study

转移性结直肠癌各疾病阶段资源利用和医疗成本:芬兰RAXO研究的一个亚组分析

2025-11-010
PRE
KRAS and NRAS mutations in Nordic population-based and real-world metastatic colorectal cancer cohorts
2025-10-210
OAAI
Cost-utility of systemic anticancer therapy (SACT) with or without metastasectomy including local ablative therapy (LAT) for metastatic colorectal cancer (mCRC) patients

系统性抗肿瘤治疗(SACT)联合或未联合转移灶切除术(包括局部消融治疗,LAT)在转移性结直肠癌(mCRC)患者中的成本-效用分析

2024-09-010
PRE
Impact of primary tumour sidedness (PTS) on demographics, resectability, and outcome after metastasectomy plus /- local ablative therapy (LAT), or systemic therapy in metastatic colorectal cancer patients (a RAXO substudy)
2023-10-010
OA
Atypical (non-V600E) BRAF mutations in metastatic colorectal cancer in population and real-world cohorts

人群和现实队列中转移性结直肠癌的非典型 (non-V600E) BRAF突变

2023-09-195
OA
Resectability, Resections, Survival Outcomes, and Quality of Life in Older Adult Patients with Metastatic Colorectal Cancer (the RAXO-Study)
2023-05-187
OAAI
Resectability and resection rates of colorectal liver metastases according to RAS and BRAF mutational status: prospective study
2022-12-134
OAAI
Resectability, conversion, and resection rates with survival according to RAS and BRAF mutations in a prospective metastatic colorectal cancer study (liver-limited subgroup in the RAXO study)
2022-06-010
OAAI
Resectability, conversion, metastasectomy and outcome according to RAS and BRAF status for metastatic colorectal cancer in the prospective RAXO study
2022-05-247
OAAI
KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer

一个现实生活和三个基于人群的北欧转移性结直肠癌队列的KRAS-G12C突变

2022-02-1618
OAAI
Quality of life in Finnish metastatic colorectal cancer patients actively treated with the aim of maximizing resection and/or local ablative therapy (RAXO-study NCT01531595)
2021-07-010
OAAI